Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence.
CRC
CRC screening
Circulating tumor DNA
Fecal immunochemical test
Non-invasive biomarkers
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
02 Mar 2024
02 Mar 2024
Historique:
revised:
20
12
2023
received:
20
07
2023
accepted:
08
02
2024
medline:
2
3
2024
pubmed:
2
3
2024
entrez:
2
3
2024
Statut:
aheadofprint
Résumé
Colorectal cancer (CRC) screening programs are most effective at reducing disease incidence and mortality through sustained screening participation. A novel blood test modality is being explored for CRC screening, but it is unclear whether it will provide sustained screening participation. This study aimed to investigate whether a circulating tumor DNA (ctDNA) blood test improved CRC screening re-participation when compared with a fecal immunochemical test (FIT) and to define the predictors of sustained CRC screening in an Australian population. South Australians who initially participated in CRC screening using a ctDNA blood test (n = 36) or FIT (n = 547) were offered the same CRC screening test approximately 2 years later through an extended phase of a randomized controlled trial. Surveys collected demographic, psychosocial, and clinical information. Predictors of CRC screening re-participation were explored using chi-square, Wilcoxon tests, and logistic regression. Participants offered a second ctDNA blood test were equally likely to re-participate in CRC screening as those who completed a FIT in the first round and who were offered the same test (61% vs 66% re-participation respectively, P = 0.6). CRC fatalism, health activation, and self-efficacy were associated with repeated screening participation. Test awareness was predictive of repeated FIT-based CRC screening. Targeted interventions to improve CRC screening awareness and increase patient health activation may improve CRC screening adherence. A ctDNA blood test may be a suitable CRC screening option to maintain CRC screening adherence in people who do not participate in screening with FIT.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Colorectal cancer (CRC) screening programs are most effective at reducing disease incidence and mortality through sustained screening participation. A novel blood test modality is being explored for CRC screening, but it is unclear whether it will provide sustained screening participation. This study aimed to investigate whether a circulating tumor DNA (ctDNA) blood test improved CRC screening re-participation when compared with a fecal immunochemical test (FIT) and to define the predictors of sustained CRC screening in an Australian population.
METHODS
METHODS
South Australians who initially participated in CRC screening using a ctDNA blood test (n = 36) or FIT (n = 547) were offered the same CRC screening test approximately 2 years later through an extended phase of a randomized controlled trial. Surveys collected demographic, psychosocial, and clinical information. Predictors of CRC screening re-participation were explored using chi-square, Wilcoxon tests, and logistic regression.
RESULTS
RESULTS
Participants offered a second ctDNA blood test were equally likely to re-participate in CRC screening as those who completed a FIT in the first round and who were offered the same test (61% vs 66% re-participation respectively, P = 0.6). CRC fatalism, health activation, and self-efficacy were associated with repeated screening participation. Test awareness was predictive of repeated FIT-based CRC screening.
CONCLUSIONS
CONCLUSIONS
Targeted interventions to improve CRC screening awareness and increase patient health activation may improve CRC screening adherence. A ctDNA blood test may be a suitable CRC screening option to maintain CRC screening adherence in people who do not participate in screening with FIT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Council SA Beat Cancer Research Project Grant
ID : APP1080541
Organisme : National Health and Medical Research Council Australia Project Grant
ID : APP1101837
Informations de copyright
© 2024 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Australian Institute of Health and Welfare. National Bowel Cancer Screening Program: monitoring report 2022. Canberra: AIHW2022.
Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am. J. Gastroenterol. 2008; 103: 1541-1549.
Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: An update. World J. Gastroenterol. 2017; 23: 3632-3642.
Triantafillidis JK, Vagianos C, Malgarinos G. Colonoscopy in colorectal cancer screening: current aspects. Indian J. Surg. Oncol. 2015; 6: 237-250.
Quintero E, Castells A, Bujanda L et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N. Engl. J. Med. 2012; 366: 697-706.
Worthington J, Lew JB, Feletto E et al. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment. PLoS ONE 2020; 15: e0227899.
Barre S, Leleu H, Benamouzig R et al. Cost-effectiveness analysis of alternative colon cancer screening strategies in the context of the French national screening program. Therap. Adv. Gastroenterol. 2020; 13 1756284820953364.
Symonds EL, Cock C, Meng R, Cole SR, Fraser RJL, Young GP. Uptake of a colorectal cancer screening blood test in people with elevated risk for cancer who cannot or will not complete a faecal occult blood test. Eur. J. Cancer Prev. 2018; 27: 425-432.
Palmer CK, Thomas MC, von Wagner C, Raine R. Reasons for non-uptake and subsequent participation in the NHS Bowel Cancer Screening Programme: a qualitative study. Br. J. Cancer 2014; 110: 1705-1711.
Cole SR, Zajac I, Gregory T et al. Psychosocial variables associated with colorectal cancer screening in South Australia. Int. J. Behav. Med. 2011; 18: 302-309.
Symonds EL, Hughes D, Flight I et al. A randomized controlled trial testing provision of fecal and blood test options on participation for colorectal cancer screening. Cancer Prev. Res. (Phila.) 2019; 12: 631-640.
Honein-AbouHaidar GN, Kastner M, Vuong V et al. Systematic review and meta-study synthesis of qualitative studies evaluating facilitators and barriers to participation in colorectal cancer screening. Cancer Epidemiol. Biomarkers Prev. 2016; 25: 907-917.
Wools A, Dapper EA, de Leeuw JR. Colorectal cancer screening participation: a systematic review. Eur. J. Public Health 2016; 26: 158-168.
Cole SR, Smith A, Wilson C, Turnbull D, Esterman A, Young GP. An advance notification letter increases participation in colorectal cancer screening. J. Med. Screen. 2007; 14: 73-75.
Goodwin BC, Ireland MJ, March S et al. Strategies for increasing participation in mail-out colorectal cancer screening programs: a systematic review and meta-analysis. Syst. Rev. 2019; 8: 257.
Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J. Med. Screen. 2003; 10: 117-122.
Symonds EL, Osborne JM, Cole SR, Bampton PA, Fraser RJ, Young GP. Factors affecting faecal immunochemical test positive rates: demographic, pathological, behavioural and environmental variables. J. Med. Screen. 2015; 22: 187-193.
Pedersen SK, Baker RT, McEvoy A et al. A two-gene blood test for methylated DNA sensitive for colorectal cancer. PLoS ONE 2015; 10: e0125041.
Deacon B, Abramowitz J. Fear of needles and vasovagal reactions among phlebotomy patients. J. Anxiety Disord. 2006; 20: 946-960.
Weinstein ND, Sandman PM, J. BS The precaution adoption process model. In: Sweeny K, Robbins ML, Cohen LM, eds. The Wiley Encyclopedia of Health Psychology. John Wiley & Sons Ltd, 2020; 495-506.
Robb KA, Miles A, Wardle J. Demographic and psychosocial factors associated with perceived risk for colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2004; 13: 366-372.
Tiro JA, Vernon SW, Hyslop T, Myers RE. Factorial validity and invariance of a survey measuring psychosocial correlates of colorectal cancer screening among African Americans and Caucasians. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 2855-2861.
Maxwell AE, Bastani R, Crespi CM, Danao LL, Cayetano RT. Behavioral mediators of colorectal cancer screening in a randomized controlled intervention trial. Prev. Med. 2011; 52: 167-173.
Brehaut JC, O'Connor AM, Wood TJ et al. Validation of a decision regret scale. Med. Decis. Making 2003; 23: 281-292.
Todorov K, Wilson C, Sharplin G, Corsini N. Faecal occult blood testing (FOBT)-based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake. Aust. Health Rev. 2018; 42: 45-52.
Wolf MS, Smith SG, Pandit AU et al. Development and Validation of the Consumer Health Activation Index. Med. Decis. Making 2018; 38: 334-343.
Flight I, Harrison NJ, Symonds EL, Young G, Wilson C. Validation of the Consumer Health Activation Index (CHAI) in general population samples of older Australians. PEC Innov. 2023; 3: 100224.
Wickham H, Averick M, Bryan J et al. Welcome to the Tidyverse. J. Open Source Softw. 2019; 4: 1686.
Sjoberg DDWK, Curry M, Lavery JA, Larmarange J. Reproducible summary tables with the gtsummary package. The R Journal 2021; 13: 570-580.
Meyer D, Hornik K. vcd: Visualizing Categorical Data. R package version 1.4-10; 2022.
Young GP, Chen G, Wilson CJ et al. “Rescue” of nonparticipants in colorectal cancer screening: a randomized controlled trial of three noninvasive test options. Cancer Prev. Res. (Phila.) 2021; 14: 803-810.
Janda M, Hughes KL, Auster JF, Leggett BA, Newman BM. Repeat participation in colorectal cancer screening utilizing fecal occult blood testing: a community-based project in a rural setting. J. Gastroenterol. Hepatol. 2010; 25: 1661-1667.
Cole SR, Gregory T, Whibley A et al. Predictors of re-participation in faecal occult blood test- based screening for colorectal cancer. Asian Pac. J. Cancer Prev. 2012; 13: 5989-5994.
Pornet C, Denis B, Perrin P, Gendre I, Launoy G. Predictors of adherence to repeat fecal occult blood test in a population-based colorectal cancer screening program. Br. J. Cancer 2014; 111: 2152-2155.
Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C. Predictors of repeat participation in the NHS bowel cancer screening programme. Br. J. Cancer 2015; 112: 199-206.
Denis B, Gendre I, Perrin P. Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study. J. Med. Screen. 2015; 22: 76-82.
Osborne JM, Wilson C, Duncan A et al. Patterns of participation over four rounds of annual fecal immunochemical test-based screening for colorectal cancer: what predicts rescreening? BMC Public Health 2017; 18: 81.
Osborne JM, Wilson C, Moore V, Gregory T, Flight I, Young GP. Sample preference for colorectal cancer screening tests: blood or stool? Open J. Prev. Med. 2012; 02: 326-331.
Murphy CC, Vernon SW, Haddock NM, Anderson ML, Chubak J, Green BB. Longitudinal predictors of colorectal cancer screening among participants in a randomized controlled trial. Prev. Med. 2014; 66: 123-130.